We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Screens for Secondary Heart Attack

By LabMedica International staff writers
Posted on 18 Sep 2018
Print article
Image: An Agilent 6490 triple quadrupole mass spectrometer (Photo courtesy of Agilent Technologies).
Image: An Agilent 6490 triple quadrupole mass spectrometer (Photo courtesy of Agilent Technologies).
Patients with a history of unstable angina and myocardial infarction (MI) are at high risk for recurrent cardiovascular events. The seven-year incidence rates of MI in non-diabetic and diabetic individuals with prior MI at baseline have been reported to be 18.8% and 45.0%, respectively.

In secondary prevention, where the vast majority of individuals have dysfunctional lipid and lipoprotein metabolism, the established risk factors for first cardiovascular events, such as dyslipidemia assessed by traditional clinical lipid profile, and blood glucose levels may not be sufficiently sensitive to predict future events, perhaps partly because of altered pathophysiology and medication use.

Scientists at the Baker Heart and Diabetes Institute (Melbourne, Australia) and their colleagues enrolled individuals between 31 and 75 years of age, with an MI or hospital admission for unstable angina 3 to 36 months previously, having plasma total cholesterol levels of between 4.0 and 7.0 mmol/L and fasting triglycerides of <5.0 mmol/L. Detailed lipidomic profiling was conducted on 5,991 participants, for whom baseline fasting plasma samples were available, representing 3,002 of those randomized to placebo and 2,989 of those assigned pravastatin.

The team extracted lipids from 10 μL human plasma with 100 μL butanol/methanol. Lipidomic analysis (342 species) was performed by liquid chromatography and electrospray ionization–tandem mass spectrometry using an Agilent 1290 liquid chromatography system combined with an Agilent 6490 triple quadrupole mass spectrometer. The relative concentration of each lipid species was calculated from the area of the resultant chromatograms relative to the corresponding internal standard.

The scientists reported that specific ceramide species, sphingolipids, phospholipids, and neutral lipids containing omega-6 fatty acids or odd-chain fatty acids were associated with future cardiovascular events (106 species) and cardiovascular death (139 species). The addition of seven lipid species to a base model (11 conventional risk factors) resulted in an increase in the C-statistics from 0.629 to 0.654 for prediction of cardiovascular events and from 0.673 to 0.727 for prediction of cardiovascular death.

The authors concluded that the improvement in the prediction of cardiovascular outcomes, above conventional risk factors, demonstrates the potential of plasma lipidomic profiles as biomarkers for cardiovascular risk stratification in secondary prevention. Peter Meikle, PhD, a professor and senior investigator of the study, said, “The test was developed after a study looked at 10,000 samples to find the biomarkers that will determine whether a person is at risk of having another heart attack. Our test will use up to ten lipid markers to better diagnose heart disease. It's a challenging, yet very exciting time. We effectively have the information and are in the process of refining the technology.” The study was published on September 6, 2018, in the journal JCI Insight.

Related Links:
Baker Heart and Diabetes Institute

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.